U.S. FDA approves Biogen's hemophilia B drug Alprolix
March 28, 2014 at 16:56 PM EDT
March 28 (Reuters) - Biogen Idec Inc has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration said on Friday.
